SCHEMBL16634244

SCHEMBL16634244

O=C(O)C=Cc1ccc(Br)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.47
EIF2AK2 P19525 1/20 0.47
CSNK2A2 P19784 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.47
KMT2A Q03164 2/20 0.47
MCL1 Q07820 2/20 0.47
STAT3 P40763 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PTGER3 P43115 3/20 0.45
PTGER2 P43116 3/20 0.45
PTGER1 P34995 2/20 0.45
GAA P10253 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16634243 1.00 BACE1 (0.47) BACE1EIF2AK2CSNK2A2CSNK2BCSNK2A1
SCHEMBL6022704 0.86 PTGER3 (0.49) EIF2AK2CSNK2A2CSNK2BCSNK2A1MAPT
SCHEMBL6022702 0.86 PTGER3 (0.49) EIF2AK2CSNK2A2CSNK2BCSNK2A1MAPT
SCHEMBL8361239 0.82 CYP2D6 (0.49) BACE1MAPTALDH1A1KDM4EMEN1
SCHEMBL165227 0.81 MAPT (0.65) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL481451 0.81 MAPT (0.65) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL29419102 0.81 MAPT (0.65) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL5448079 0.81 EIF2AK2 (0.55) BACE1EIF2AK2CSNK2A2CSNK2BCSNK2A1
Hydrochloric Acid SCHEMBL10594850 0.81 CYP2D6 (0.48) BACE1MAPTALDH1A1KDM4EMEN1
SCHEMBL4265141 0.80 BACE1 (0.72) BACE1MAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828243-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2018-10-17 EP disclosed
US-9499538-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, ESRRG, GPER1 BACE1 3183/4885EIF2AK2 2429/4885CSNK2A2 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.